LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USPPRNewsWire • 05/12/22
Lannett Company, Inc. (LCI) CEO Timothy Crew on Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
LANNETT TO REPORT FISCAL 2022 THIRD-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, MAY 4PRNewsWire • 04/27/22
LANNETT ANNOUNCES RECEIPT OF NOTICE OF NON-COMPLIANCE FROM NYSE RELATED TO STOCK PRICEPRNewsWire • 03/18/22
LANNETT Announces sale of liquid drug manufacturing plant and other assets for $10.5 millionPRNewsWire • 03/04/22
Lannett Company's (LCI) CEO Tim Crew on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 02/04/22
LANNETT REPORTS FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS; REVISES DOWN FULL-YEAR GUIDANCEPRNewsWire • 02/03/22
LANNETT TO REPORT FISCAL 2022 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON THURSDAY, FEBRUARY 3PRNewsWire • 01/27/22
LANNETT ANNOUNCES FDA COMPLETES REVIEW OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINEPRNewsWire • 01/21/22
LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINEPRNewsWire • 12/20/21
Lannett Company, Inc. (LCI) CEO Tim Crew on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/04/21
Lannett Reports Fiscal 2022 First-Quarter Financial Results; Revises Down Full-year GuidancePRNewsWire • 11/03/21
Lannett To Report Fiscal 2022 First-quarter Financial Results, Host Conference Call On Wednesday, November 3PRNewsWire • 10/28/21
Lannett Company, Inc.'s (LCI) CEO Tim Crew on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/26/21